tezacaftor/ivacaftor
E1191491
UNEXPLORED
Tezacaftor/ivacaftor is a combination cystic fibrosis therapy that improves the function of defective CFTR protein in patients with specific genetic mutations.
All labels observed (1)
| Label | Occurrences |
|---|---|
| tezacaftor/ivacaftor canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T15982891 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: tezacaftor/ivacaftor Context triple: [Vertex Pharmaceuticals, notableProduct, tezacaftor/ivacaftor]
-
A.
lumacaftor/ivacaftor
Lumacaftor/ivacaftor is a combination cystic fibrosis medication that improves the function of defective CFTR proteins in patients with specific genetic mutations.
-
B.
ivacaftor
Ivacaftor is a precision medicine drug used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
-
C.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
D.
CFTR
CFTR is a Canadian AM radio station based in Toronto, Ontario, best known for its all-news format and branding as CityNews 680.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: tezacaftor/ivacaftor Target entity description: Tezacaftor/ivacaftor is a combination cystic fibrosis therapy that improves the function of defective CFTR protein in patients with specific genetic mutations.
-
A.
lumacaftor/ivacaftor
Lumacaftor/ivacaftor is a combination cystic fibrosis medication that improves the function of defective CFTR proteins in patients with specific genetic mutations.
-
B.
ivacaftor
Ivacaftor is a precision medicine drug used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
-
C.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
D.
CFTR
CFTR is a Canadian AM radio station based in Toronto, Ontario, best known for its all-news format and branding as CityNews 680.
-
E.
Kalydeco
Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.